Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-year quality-of-life study of Mavenclad in highly active relapsing multiple sclerosis
NL-OMON48712Phase 4Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cladribine in multiple sclerosis (MS), sponsored by Merck & Co. Primary endpoint: Change in MSQoL-54 physical and mental health composite scores. Started Jul 2018; status: active, not recruiting.
02
Drugs
cladribine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON48712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48712.